CSL Behring and the GKV-Spitzenverband reimburse price of Gene Therapy for Haemophilia B

CSL Behring and the GKV-Spitzenverband (National Association of Statutory Health Insurance Funds) have successfully concluded negotiations on the reimbursement price of HEMGENIX^®.

This agreement marks the availability of the first gene therapy approved in Europe for haemophilia B under an innovative, national, success-based reimbursement model, being implemented for the first time in Germany, CSL said in a press release.

HEMGENIX^® represents significant progress in the treatment of haemophilia B. The aim of this one-time gene therapy is to eliminate the need for regular factor IX infusions, thereby offering patients the possibility of more freedom from prophylaxis and significantly improving their quality of life. This development not only provides substantial relief for those affected but also has the potential to reduce long-term costs for the healthcare system.

‘The performance-based payment model at national level which was agreed with the GKV-Spitzenverband is unique in Germany. It addresses key reimbursement challenges, such as the question of long-term efficacy, which is inherent for any one-time therapy.  Reimbursement is linked to treatment success of the individual patient,’ explains Stefan Neudoerfer, CSL Behring’s chief negotiator in Germany.

Moreover, this reimbursement model reflects the high therapeutic and innovative value of HEMGENIX^® and sets new standards for integrating innovative gene therapies into the German healthcare system.

‘The agreement on the reimbursement price of HEMGENIX^® is a decisive step for the care of people with haemophilia B in Germany. It enables access to a groundbreaking therapy and recognises the long-term medical and economic benefits of gene therapy,’ explains Christian Wieszner, Managing Director of CSL Behring Germany.